Is Amarin Corporation plc a good investment? Amarin Corporation plc (AMRN) is currently trading at 15.24 USD. Market analysts have a consensus price target of 12.50 USD. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Amarin Corporation plc is expected to release its next earnings report on July 29, 2026. The market consensus estimate for Forward EPS is 0.98.
No, it does not currently pay a dividend.
Amarin Corporation plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of -1.60.
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Split Date | Split Ratio to 1 |
|---|---|
| April 11, 2025 | 0.050000 |
| Jan. 18, 2008 | 0.100000 |
| Oct. 19, 1998 | 0.100000 |
Community Discussion